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Implementation of international guidelines for the treatment of epileptic spasms, is 
challenging when access to adrenocorticotrophic hormone (ACTH) and vigabatrin is 
restricted, especially in Low and Middle Income Countries (LMIC). Oral corticosteroids are 
alternative interventions but evidence for the optimal agent, dose, duration, efficacy and 
long-term effects are lacking.  
A systematic review of the literature was performed to assess the quality of evidence of 
prednisone and prednisolone (oral corticosteroids) for the management of epileptic spasms.  
There is level C recommendation based on class III evidence to support the efficacy of oral 
corticosteroids for the acute clinical control of epileptic spasms and EEG resolution. Efficacy 
of oral corticosteroids in comparison to the internationally recommended intervention of 
ACTH has class IV evidence supporting level U recommendation. Similarly, there is no data 
on the risk of relapse with oral corticosteroids (class IV, level U), compared to ACTH. There 
is class IV evidence supporting level U recommendation for the safety of oral corticosteroids 
and class II evidence for level B recommendation for ACTH. In terms of oral corticosteroids 
and effects on long-term development there is class IV evidence leading to level U 
recommendation, compared to class III evidence supporting level C recommendation for 
ACTH. 
Randomized controlled studies are needed to compare oral corticosteroids with ACTH, the 
optimal dosage and regimen as well as the long-term neurodevelopmental outcomes. Based 
on the limited existing studies a treatment guideline for LMIC is proposed which could be 
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Access to hormonal and synthetic adrenocorticotrophic hormone (ACTH) is limited in many 
regions of the world [1]. This report explores the evidence to support use of oral 
corticosteroids, namely prednisolone or prednisone, in comparison to ACTH and other 
agents in the management of children with epileptic spasms (ES). 
The incidence of childhood epilepsy is highest in the infantile period and epileptic spasms 
are the most common seizure type in this age period [2].  
Epileptic spasms are characterized by a brief contraction followed by a sustained tonic 
contraction of the neck, trunk, upper and lower legs and may be flexor, extensor or mixed[3]. 
They tend to occur in clusters, usually while awakening or just before sleep[4]. Spasms are 
frequently misdiagnosed with conditions such as colic, gastrooesophageal reflux and 
constipation, which results in delayed intervention[5]. The diagnosis of epileptic spasms is 
based on the semiology of the seizure and the interictal pattern of hypsarrhythmia on the 
EEG [6]. Hypsarrhythmia is defined as random high voltage slow waves accompanied by 
focal, multifocal or generalized spikes [7]. Variations from classic hypsarrhythmia are called 
modified hypsarrhythmia and may include focality, burst suppression, slow waves without 
spikes and partial preservation of the background [5]. 
The incidence of epileptic spasms in high income countries range between 0.25 and 0.42 
per 1000 live births per year, peak onset is between 4-6 months, with a slight male 
preponderance [8]. The term “epileptic spasms” replaced “infantile spasms”, as the seizure 
type may persist or have the potential to develop beyond the infantile period [9]. 
The United Kingdom Infantile Spasms Study (UKISS) found that the most common 
aetiologies for ES were hypoxic ischaemic encephalopathy (10%), chromosomal (8%), 
cerebral malformations (8%), cerebrovascular disease (8%), Tuberous Sclerosis Complex 
(TSC) (7%), periventricular leukomalacia or haemorrhage (5%) but in 33% no cause could 
be identified. [10] Data was collected from a high income resource equipped setting. Data is 
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limited on epilepsy in Africa in general, especially from sub-Saharan Africa, and even less so 
for this specific seizure type. A study based in rural Uganda in 1997, found that 7 out of 440 
children with epilepsy, had a history suggestive of “infantile spasms”[11]. However, this may 
be an underestimation, since lack of resources, such as EEG, made it challenging to make a 
syndromic diagnosis[11]. 
Additional challenges facing Low and Middle Income Countries (LMIC) include greater 
numbers of aetiologies, such as perinatal asphyxia, which is associated with worse long 
term outcome [12]. 
Epileptic spasms are difficult to treat and associated with a high morbidity, with up to 90% of 
patients having intellectual disability [5, 13]. The persistence of hypsarrhythmia appears to 
be associated with ongoing epileptic encephalopathy, as such it is important to treat this 
finding until there is resolution on the EEG.[5] This differs from standard approaches in the 
management of epilepsy, where treatment of clinical events is promoted. For infants with 
epileptic spasms “normalization” of the EEG plays a critical role with regards to long-term 
developmental outcome. International evidence based recommendations support use of 
ACTH graded at level B and vigabatrin at level C, as graded according to the American 
Academy of Neurology Practice Parameters following systematic review [14, 15]. According 
to the Cochrane review by Hancock et al hormonal treatment resolves spasms in more 
infants than vigabatrin, and if prednisolone or vigabatrin are used, high dose is 
recommended [16].  
The lag time refers to the time taken between ES onset and intervention with treatment. 
Early cessation of spasms and a shorter lag time to treatment result in a reduced total 
duration of epileptic encephalopathy and resultant developmental delay [17]. Prolonged lag 
time and acquired aetiologies (e.g. HIE, post-infectious) in LMICs result in lower rates of 
spasm freedom compared to high income countries. This is further compounded by lack of 
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health-seeking behaviour of parents, lack of awareness among health care professionals 
and inappropriate antiepileptic drug use [18]. 
A systematic review of the literature was undertaken to establish the quality of evidence 
relating to the use of oral prednisolone and prednisone in the management of children with 
epileptic spasms in comparison to agents such as ACTH and vigabatrin. This review was 
driven by the need to develop a recommendation to standardize a safe and effective 
regimen using this product over other agents, such as ACTH and vigabatrin in LMICs, where 
access to these internationally recommended agents is lacking. 
 
Systematic review 
Using the MeSH terms “infantile spasms” and “prednisolone” and keywords “epileptic 
spasms”, “treatment”, “management”, “prednisone” and “oral corticosteroids” in Pubmed, 
Web of Science, Scopus incl. Embase, Medline, Africa-Wide, Cinahl, Cochrane reviews and 
clinical trials.com a total of 114 studies were found between 1990-2017, n=96 were excluded 
as they did not address the study question. There were n=18 studies in total, n=14 
addressing the intervention and immediate outcome and n=4 the long-term outcome [17, 19-
21]. Search terms were broad to encompass any studies which utilised oral corticosteroids in 
the management of ES. Studies were critiqued for directness to the study question of 
“efficacy in the management of ES” and consistency in study methodology across studies to 
permit comparison of outcome data. Inclusion criteria included clinical human studies and 
articles in English. Review articles were checked for additional papers not captured by the 
search.  Quality of data was graded according to the American Academy of Neurology 
(AAN) practice parameters [15]. In accordance with AAN practice parameters, level A 
evidence recommendations are established as effective, ineffective or harmful, level B 
probably effective, ineffective or harmful, level C possibly effective, ineffective or harmful and 
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level U data is inadequate or conflicting [15, 22]. Findings from the included studies are 
summarised in Table 1, based on expert opinion.  
 
Management of epileptic spasms 
Standardized management protocols for infants with epileptic spasms have resulted in an 
increase of affected patients receiving recommended first-line treatment, with improved 
remission rates three months after diagnosis [23].  For children whose spasms result from 
aetiologies, excluding TSC, ACTH is the preferred first line intervention (level B 
recommendation), at either low or high dose (level B recommendation)[14]. Evidence 
supports a level A recommendation that vigabatrin should be the first line treatment for 
epileptic spasms in children with TSC [24]. According to the meta-analysis in 2012, there is 
insufficient evidence to recommend the use of oral corticosteroids for the short-term 
treatment of epileptic spasms (level U recommendation). There is weak evidence that the 
use of ACTH or prednisolone, in children who were previously classified as having 
cryptogenic epilepsy may lead to an improved developmental outcome (level C 
recommendation) [14], but no data specifically addressing prednisone. 
Oral corticosteroids, such as prednisone and prednisolone, are increasingly being used off-
label for the treatment of epileptic spasms [1, 14, 25]. The product is less expensive, easy to 
administer and readily available worldwide[26]. Prednisolone is the active form of prednisone 
and should not be considered as equivalent treatments for infants, who have a reduced 
capacity to metabolise prednisone in the first 6 months of life [27]. Prednisone is not as 
effective as its active form[27]. In Africa, most institutions will have access to prednisone 
rather than prednisolone. The mechanism of action of prednisone/prednisolone and ACTH in 
epileptic spasms in not known. It has been proposed that ACTH may act via downstream 
cortisol effects as well as central melanocortin receptor signalling, therefore the potential 
superiority of ACTH is mechanistically plausible [28]. 
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Access to ACTH is limited, especially in resource-poor settings, by high cost, discomfort 
from injections and duration of hospitalization [18]. In the US, after Questcor acquired the 
rights to ACTH the price increased dramatically and since then the company has maintained 
the monopoly. ACTH (natural gel) costs approximately US$150 000 per treatment course 
compared to US$200 for prednisolone[1]. In South Africa, a 10 day course of ACTH 
(synthetic) costs approximately ZAR200 000 (US$17 250) and 14 day course of prednisone 
ZAR17 (US$1,5). The National Essential Medicines List Committee, appointed by the 
Minister of Health in South Africa, is responsible for formulating and revising the National 
List of Essential Medicines, in order to guide rational use of these essential medicines [29]. 
Based on issues of cost and access to care in 2016 the South African Essential Drug 
committee removed ACTH and vigabatrin from the national code list [30]. In a setting where 
previously there was capacity for treatment of ES in line with international recommendations, 
this policy returned the country to the situation evident in most other sub-Saharan Africa 
settings, where the only viable agent is likely to be prednisone. As a result an urgent national 
and regional need arose to establish an alternate evidence based guideline for the 
management of ES using available agents.  
Whilst there is a significant body of data for the management of ES with ACTH which 
supported its inclusion in guidelines and Cochrane review [14, 16], based on the systematic 
review (table 1) the same cannot be said for oral prednisone or prednisolone. Table 1 
illustrates this in the summaries of the existing studies. Of the identified studies assessing 
the use of prednisolone, prednisone or methylprednisone there was marked variation 
evident in study methodologies, limiting comparison across studies. There was 1 class I 
study, 6 class II studies and 11 retrospective observational or uncontrolled comparative 




Optimal cessation of spasms 
Of the studies, the UKISS study was not powered enough to compare hormonal subgroups, 
however, prednisolone given at 40-60mg/day resulted in a remission rate of 70% and ACTH 
76% at the final clinical assessment at 14 months[20]. The difference was not significant and 
neither was the risk of relapse between the groups [20]. A retrospective observational class 
III study, by Kossoff et al (n=15), found no statistical difference between ACTH and oral 
prednisolone, prescribed at a dose of 40-45mg/day, in the resolution of spasms after 2 
weeks [31]. The study was underpowered to detect a significant difference between ACTH 
and prednisolone, although a large difference in favour of ACTH was reported. According to 
Arya et al 2mg/kg of prednisolone was less effective compared to ACTH [25] and 
Chellamuthu et al concluded that a significantly higher proportion of children had spasm 
cessation on day 14 who had received high dose prednisolone (4mg/kg/day) compared to 
those who received half the dose [18]. In the same year, Hussain et al demonstrated that 
very high dose prednisolone, 8mg/kg/day, had a significantly greater efficacy than lower 
doses reported from previous studies[32]. O’Callaghan et al in their 2017 report concluded 
that the combination of hormonal therapy and vigabatrin, was statistically more effective at 
stopping epileptic spasms than hormonal therapy alone. However, due to the lack of 
randomization of the hormonal group, it could not be determined if ACTH or prednisolone 
was more effective[33]. Furthermore, the diversity of ACTH formulations, such as natural 
versus synthetic, full-length ACTH vs n-terminal truncated ACTH, depot vs non-depot 
administration may influence efficacy and to some extent outcomes across studies. 
 
The lack of consistency in study methodologies, directness in study questions and class I 
studies across reports limits forming a consensus on the evidence to support the use of 
prednisolone, especially as a replacement to ACTH. There was marked variation in the 
inclusion criteria, aetiologies of spasms from LMIC and HIC, drop-outs, treatment lag, 
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definition of response, proportion of low-risk/high risk, symptomatic patients, dose and 
duration of therapy and length of follow-up limiting comparison across studies. In addition, 
the optimal dose of prednisone and prednisolone still needs to be determined. For optimal 
care, combination therapy may be needed, as evidenced by ICISS study [33]. 
In terms of other steroid formulations, 57% of patients responded to dexamethasone in a 
retrospective observational study by Haberlandt et al, class III study, compared to 64% to 
ACTH. They concluded that pulsed dexamethasone is a suitable alternative to ACTH, 
however, relapse rate was not stated and long term outcomes not measured [34]. More 
recently, a small study by Yeh et al, n=14 class III study, concluded that short-term 
methylprednisolone pulsed therapy resulted in rapid resolution of epileptic spasms and 
hypsarrythmia without serious adverse effects [35]. There is insufficient evidence to 
recommend other therapies in the treatment of epileptic spasms such as valproic acid, 
nitrazepam, pyridoxine, zonisamide, thyrotropin-releasing hormone, topiramate, 
levetiracetam and ketogenic diet [14, 36].  
Adverse effects of steroids are a concern, particularly the increased risk of infections, such 
as tuberculosis, in LMICs, and the complications from immunodeficiency in HIV-infected 
infants. Other side effects include increased appetite, weight gain, hypertension, cushingoid 
facies, irritability, glycosuria and cerebral atrophy [14, 18]. It is advisable that prior to starting 
treatment, for HIV status, chest x-ray, tuberculin skin test, baseline weight and blood 
pressure to be recorded[18].  
 
Developmental Outcome 
According to UKISS, there was no difference in the neurodevelopmental outcome in overall 
data on children with ES who received hormonal treatment or vigabatrin at 14 months and 4 
years of age. However, there was significant improvement in developmental scores in those 
who received hormonal treatment without an identifiable aetiology. [20, 21] In the same 
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study, an increase in lag time to treatment was significantly associated with a lower 
developmental score at 4 years after adjusting for age of onset, aetiology and treatment [17].  
Factors that result in a more favourable long term cognitive outcome include a shorter lag 
time to treatment with hormonal treatment or vigabatrin (level C) [14], shorter duration of 
hypsarrhythmia[37] and “cryptogenic” cause of epileptic spasms[38]. There are currently no 





Further randomised studies are needed to compare oral corticosteroids to ACTH and to 
determine the optimal dose, comparison efficacy, as well as long-term studies looking at the 
neurodevelopmental outcomes of these groups. High dose oral prednisolone appears to be 
evolving as a strong alternate candidate for infants with epileptic spasms, especially in 
settings where access to ACTH is not viable. In children with epileptic spasms and TSC 
vigabatrin remains the first line recommended agent. In settings where oral corticosteroids 
are used, standardized protocols should be in place and outcomes audited. Based on the 
accumulated data a recommendation has been compiled (Figure 1) for settings without 
reliable access to ACTH and vigabatrin. 
Whilst there appears to be efficacy using oral corticosteroids for children with ES (level C 
recommendation), the optimal dose has not been defined beyond limited case series 
promoting higher doses. Of concern it remains unclear whether these children have a 
disadvantage with regard to their relapse rate, subsequent epilepsy syndrome development 
and neurodevelopmental outcome. 
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In summary, there is class III evidence supporting a level C recommendation for the efficacy 
of oral corticosteroids for the acute clinical control of epileptic spasms and EEG resolution. 
Use of oral corticosteroids in comparison to the internationally recommended intervention of 
ACTH has class IV evidence resulting in a level U recommendation. Similarly, the risk of 
relapse with oral corticosteroids has class IV evidence and level U recommendation, and 
compared to ACTH, class IV evidence with level U recommendation. There is class IV 
evidence resulting in level U recommendation for the safety of oral corticosteroids and class 
II evidence supporting level B recommendation for ACTH. In terms of oral corticosteroids 
and effects on long-term development evidence is class IV evidence leading to level U 






Table I: Overview of the studies which included oral corticosteroids in the management of epileptic spasms.  
       
Author, year 
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447 total;  
366 with 
hypsarrhythmia




twice/day for 2 
weeks followed 
by gradual 
tapering over 2 
weeks, 85 
prednisolone 
10mg 4 times 







divided into 2 
doses 
 













ratio (OR) 5.2, 
prednisolone 
OR 8, ACTH OR 
10.2 cessation 
of spasms and 
resolution of 
hypsarrhythmia 

















for 3 days 
followed by 
tapering doses of 
prednisolone 
1mg/kg 2 doses, 
rapidly reduced 










follow up till 
3 months 
















Relapse rate for 
spasms 45.5% 
55.5% remained 
seizure free after 
discontinuing steroids 















26 IVIG vs 25 
prednisone 




60mg/day) for 2 
weeks followed 
by 6-8 week taper 
OR prednisone 1-
2mg/kg/day (max 
60mg/day) for 2-4 
weeks followed 
by 4-6 week taper 




Only 1 other 
study (Bara, 
et al) with 
























































ACTH  (40IU 
alternate days for 
2 weeks), 134 
prednisolone 
(10mg 4 
times/day) for 2 
weeks, tapered by 
10mg every 5 









e et al, Ware 
et al, 
Mohamed et 
























spasms in 89% 
on combination 




days 13 & 14, 
19% relapsed 
by day 42 (33 
on combination 




Day 14-42, no spasms 
in 72% combination 






vs. 55% hormonal 
therapy (p=0.023). 
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230 total – 







twice/day for 2 
weeks followed 
by gradual 
weaning over 2 
weeks, 
prednisolone 
10mg 4 times 










with doses in 
ICISS, Ware et 
al, 
Mohammed 
et al and 
follow up in 
the short and 


























After 2 weeks, 
55% responded 






. Relapse rate 
highest for oral 
corticosteroids, 
24%. 
After 3 months, 
sustained response to 
ACTH significantly 
higher than vigabatrin 







e et al 
2015 









vs. 49 ACTH 
Prednisolone 
10mg 4 times/day 




week over 3 
weeks or ACTH 
40IU alt days for 2 
weeks  
Yes Consistent 
with doses in 
ICISS, Ware et 
al, 
Mohammed 
et al and 
follow up in 

















of spasms with 
prednisolone at 




group and 8 
from ACTH 
group. 
Follow up study at 3 
months showed 
significantly better 
spasm control if 
treated with 
prednisolone 64.6% 
than ACTH 38.8% 
p=0.01. Spasm control 
at 6 months, 58.3% 
prednisolone and 
44.9% ACTH p=0.19. 
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followed by taper 
over the next 3 
weeks 
 
limited to 30 
mins and not 
done at every 









week at each 
testing period 








vs. 38.7% on 
ACTH 
(p=0.079).  








At 12 months spasm 
cessation 56.2% 
prednisolone and 
40.8% ACTH p=0.13. 
After 12 months no 
difference in relapse 
between groups.  
Cognitive outcomes 
not assessed 









15 ACTH vs 5 
Prednisolone 
ACTH 1.9mg/m2  
alt days followed 
by a tapering 
schedule from 



















used a second 
line agents if 





ACTH vs. 20% 
response to 
prednisolone 
(p=0.03) after 2 
weeks 
58% relapsed on 
ACTH, 100% relapse, 
follow up between 6-
38 months from 
spasm onset (p=0.26). 
Cognitive outcomes 
not assessed 








20 prednisolone Prednisolone 
10mg 4 times/day 
for 2 weeks 
reduced weekly 
Yes Consistent 








of spasms after 
2 weeks 
prednisolone 
Median follow up 
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weeks course 
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et al, Ware et 
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developmental 
quotient after 













32 low dose 
prednisolone 
vs. 31 high dose 
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Prednisolone 
2mg/kg/day vs.  
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by tapering over 2 
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consistent 
with Kossoff 
et al, follow 
up only for 6 
months, EEG 
recorded for 
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with doses in 
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Wanigasingh




























Follow up 21 months, 
none who received 
prednisolone with 
cryptogenic aetiology 
relapsed and 10 with 
symptomatic 
aetiology relapsed 
(not specified how 
many received 
prednisolone or not 
treated with 
protocol), 4 of the 6 
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UKISS 40mg daily 
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every 5 days, 
Vigabatrin 25-
50mg/kg/day 
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al, Aicardi et 
al). 
61.1% response 





1 relapsed on steroids 
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weeks, followed 
by tapering over 6 
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spasms at 2 
weeks. 





than high dose 
prednisolone 
used by Yeh et 
al. Results 
complicated 
by use of 
ineffective 
antiseizure 











60% had relapse or 
continuation of 
spasms at follow up. 
Cognitive outcomes 
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by tapering over 2 
weeks 
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15 Response to 
prednisolone at 
40-45mg/kg/day 
in 3 divided doses 
for 2 weeks 
followed by 
tapering over 2 
weeks 
Yes Consistent 













(87%) to ACTH 






previous data.  
67% spasm free 




No long term data 
available 










23 ACTH, 72 
prednisolone 
ACTH 20-
40IU/day for 4 
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tapered over 2 
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Prednisolone 2-
3mg/kg/day in 2 
divided doses 
total duration 
incl. tapering 6-8 
weeks 





































Follow up variable 6-
10 months. 33% ACTH 
remained spasm free, 
24% prednisolone 
spasm free. No long 
term data re: relapse 





Lux et al  
2005 
(UKISS) 












10mg 4 times/day 
for 2 weeks 
followed by 
tapering by 10mg 
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ACTH 40-60IU alt 
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No difference in 
spasm control at 12-
14 months. No 
identified aetiology 
led to better 
developmental 
outcomes at 14 
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• Infants with TSC are recommended to receive vigabatrin as first line intervention and the role for 
additional homonal therapy has not been reported. 
Confirmed diagnosis: 
Epileptic spasms with hypsarrhythmia on EEG 
with/without Tuberous Sclerosis Complex 
Initiate vigabatrin 100mg/kg/day, 
can increase dose to 
150mg/kg/day if needed  
AND prednisolone 4mg/kg/day 
(max 60mg/day) for 2 weeks, 
followed by taper over 4 weeks 
(level U)* 
Follow-up visits: 
EEG and clinical assessment  
Monitor blood pressure, body weight, urinary glucose, cushingoid facies, 
odema, irritability, drowsiness and for infections  
 
After 2 weeks: 
Repeat EEG and assess if spasm cessation 
Continue treatment as above and reassess at regular intervals 
Prior to starting treatment, HIV status, chest x-ray, tuberculin skin 
test, baseline weight and blood pressure should be documented 
 
Prednisolone 4mg/kg/day  
(max 60mg/day) for 2 weeks 





Initiate ACTH 150IU/m2 /day 
for aetiology other than TSC 
(level B). 
For TSC, vigabatrin 
100mg/kg/day, can increase 
dose to 150mg/kg/day if 
needed (level A). 
If ACTH and vigabatrin 
available 
If vigabatrin available but 
ACTH NOT available 
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SEIZURE - EUROPEAN JOURNAL OF EPILEPSY 
AUTHOR INFORMATION PACK 






• Impact Factor 
• Abstracting and Indexing 
• Editorial Board 










Seizure - European Journal of Epilepsy  is an international journal owned by Epilepsy Action  (the largest 
member led epilepsy organisation in the UK). It provides a forum for papers on all topics related to 
epilepsy  and seizure disorders . 
Seizure  focuses especially on clinical  and psychosocial  aspects, but will publish papers on the basic 
sciences related to the condition itself, the differential diagnosis, natural history and epidemiology of 
seizures , as well as the investigation and practical management of seizure disorders (including drug 
treatment, neurosurgery and non-medical or behavioural treatments). 
The journal reflects the social and psychological burden and impact of the condition on people with 
epilepsy, their families and society at large, and the methods and ideas that may help to alleviate 
the disability and stigma, which the condition may cause. The journal aims to share and disseminate 
knowledge between all disciplines that work in the field of epilepsy. 
AUDIENCE 
. 
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GUIDE FOR AUTHORS 
. 
Your Paper Your Way 
 We now differentiate between the requirements for new and revised submissions. You may choose to 
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submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when 
your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' 
for acceptance and provide the items required for the publication of your article. 
To find out more, please visit the Preparation section below. 
INTRODUCTION 
Types of articles 
Seizure - European Journal of Epilepsy  publishes the following types of article: 
1.1 Peer-reviewed articles 
a. Full reviews. 
 Seizure welcomes comprehensive reviews on all subjects relating to epilepsy and other seizure 
disorders. Authors planning/proposing are invited to discuss their ideas with Editor-in-Chief prior to 
submission. Full reviews should be preceded by an abstract. Full reviews should not exceed 7,000 
words, include no more than 6 figures or tables and 150 references. 
b. Focused reviews. 
 Seizure is keen to publish focused reviews, especially on the latest developments in particular fields or 
on topics which are currently debated by clinicians and researchers. Authors are welcome to approach 
the Editor-in-Chief with their idea for a focused review prior to submission. Focused reviews should 
be preceded by an abstract. Focused reviews should be 1,500-2,500 words, and include no more than 
3 figures or tables and 50 references. 
c. Full-length original research articles. 
 The body of the text of these articles should be limited in length to 4,000 words, and there 
should be a maximum of 6 figures or tables. Additional figures, tables and other material (such as 
associated videos) can be submitted as online only Supporting Information (see section 'preparation 
of manuscripts' for further details). Full length research articles should be preceded by an abstract. 
The body of the text of the article should be clearly structured into 1) Introduction, 2) Methods 3) 
Results, 4) Discussion, 5) Conclusion and 6) References. 
d. Short communications. 
 Comprise a number of different kinds of previously unpublished materials including short reports or 
small case series. Short communications should be preceded by an abstract. The body of the text is 
limited to 1,400 words. There are no more than 12 references, and 2 figures or tables (combined). 
e. Case reports (Clinical Letters) , see also Interactive Case Insights  below 
Seizure will also publish particularly instructive case reports in the format of Clinical Letters. Clinical 
Letters will not be preceded by an abstract. The word count is strictly limited to 1,000 words excluding 
title page information, references, and any figure or table legends. Clinical Letters can only include a 
maximum of 4 references and 2 figures or tables (combined), authors may include additional reading 
as supplementary material. 
f. Letters to the Editor 
 Letters containing critical assessment of papers recently published in the Seizure - European Journal 
of Epilepsy  will be considered for publication in the correspondence section. Letters should not exceed 
1,000 words including references as necessary, one table or one figure. Letters should be typed in 
double spacing, should have a heading and no abbreviations. If related to a previously published 
article, the article should be identified by title, author(s), and volume/page numbers. All letters are 
subject to editorial review. At the Editor's discretion, a letter may be sent to authors of the original 
paper for comment, and both letter and reply may be published together. 
1.2 Editorially-reviewed material 
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Other contributions than original research or review articles will be published at the discretion of the 
Editor-in-Chief, with only editorial review. Such material includes: obituaries, workshop reports and 
conference summaries, letters/commentary to the Editors (500 word limit, exceptionally including 
figures or tables), special (brief) reports from ILAE Commissions or other working groups, book 
reviews and announcements. 
1.3 Supplements / Special Editions 
 The Editor-in-Chief invites ideas for supplements or special editions of Seizure including meeting 
abstracts. Such materials may be published, but only after prior arrangement with the Editor-in-Chief. 
Supplements will incur a charge. The page rate for proposed supplements can be negotiated with the 
Editor-in- Chief. Special editions are issues of Seizure wholly or partially dedicated to one particular 
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topic. They may be edited or co-edited by internationally recognised experts in their field. Such experts 
do not need to be members of the Editorial Board of Seizure and are welcome to approach the Editorin- 
Chief with their ideas. Special editions of Seizure would be expected to contain the same kind of 
manuscripts which are published in normal editions. 
Submission checklist 
 You can use this list to carry out a final check of your submission before you send it to the journal for 
review. Please check the relevant section in this Guide for Authors for more details. 
Ensure that the following items are present: 
 One author has been designated as the corresponding author with contact details: 
• E-mail address 
• Full postal address 
All necessary files have been uploaded: 
Manuscript : 
• Include keywords 
• All figures (include relevant captions) 
• All tables (including titles, description, footnotes) 
• Ensure all figure and table citations in the text match the files provided 
• Indicate clearly if color should be used for any figures in print 
Graphical Abstracts / Highlights files  (where applicable) 
Supplemental files  (where applicable) 
Further considerations 
• Manuscript has been 'spell checked' and 'grammar checked' 
• All references mentioned in the Reference List are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources (including the 
Internet) 
• A competing interests statement is provided, even if the authors have no competing interests to 
declare 
• Journal policies detailed in this guide have been reviewed 
• Referee suggestions and contact details provided, based on journal requirements 
For further information, visit our Support Center . 
BEFORE YOU BEGIN 
Ethics in publishing 
 Please see our information pages on Ethics in publishing  and Ethical guidelines for journal publication . 
Declaration of interest 
 All authors must disclose any financial and personal relationships with other people or organizations 
that could inappropriately influence (bias) their work. Examples of potential competing interests 
include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent 
applications/registrations, and grants or other funding. Authors must disclose any interests in two 
places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the 
manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations 
of interest: none'. This summary statement will be ultimately published if the article is accepted. 
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2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the 
journal's official records. It is important for potential interests to be declared in both places and that 
the information matches. More information . 
Submission declaration and verification 
 Submission of an article implies that the work described has not been published previously (except in 
the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent 
publication ' for more information), that it is not under consideration for publication elsewhere, that 
its publication is approved by all authors and tacitly or explicitly by the responsible authorities where 
the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in 
English or in any other language, including electronically without the written consent of the copyrightholder. 
To verify originality, your article may be checked by the originality detection service Crossref 
Similarity Check . 
Preprints 
 Please note that preprints  can be shared anywhere at any time, in line with Elsevier's sharing policy . 
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Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, 
redundant or concurrent publication ' for more information). 
Use of inclusive language 
 Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, 
and promotes equal opportunities. Articles should make no assumptions about the beliefs or 
commitments of any reader, should contain nothing which might imply that one individual is superior 
to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive 
language throughout. Authors should ensure that writing is free from bias, for instance by using 'he 
or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping 
(e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess'). 
Changes to authorship 
 Authors are expected to consider carefully the list and order of authors before  submitting their 
manuscript and provide the definitive list of authors at the time of the original submission. Any 
addition, deletion or rearrangement of author names in the authorship list should be made only 
before  the manuscript has been accepted and only if approved by the journal Editor. To request such 
a change, the Editor must receive the following from the corresponding author : (a) the reason 
for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they 
agree with the addition, removal or rearrangement. In the case of addition or removal of authors, 
this includes confirmation from the author being added or removed. 
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of 
authors after  the manuscript has been accepted. While the Editor considers the request, publication 
of the manuscript will be suspended. If the manuscript has already been published in an online issue, 
any requests approved by the Editor will result in a corrigendum. 
Article transfer service 
 This journal is part of our Article Transfer Service. This means that if the Editor feels your article is 
more suitable in one of our other participating journals, then you may be asked to consider transferring 
the article to one of those. If you agree, your article will be transferred automatically on your behalf 
with no need to reformat. Please note that your article will be reviewed again by the new journal. 
More information . 
Copyright 
 Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see 
more information  on this). An e-mail will be sent to the corresponding author confirming receipt of 
the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version 
of this agreement. 
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal 
circulation within their institutions. Permission  of the Publisher is required for resale or distribution 
outside the institution and for all other derivative works, including compilations and translations. If 
excerpts from other copyrighted works are included, the author(s) must obtain written permission 
from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms  for 
use by authors in these cases. 
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For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 
'Exclusive License Agreement' (more information ). Permitted third party reuse of gold open access 
articles is determined by the author's choice of user license . 
Author rights 
 As an author you (or your employer or institution) have certain rights to reuse your work. More 
information . 
Elsevier supports responsible sharing 
 Find out how you can share your research  published in Elsevier journals. 
Role of the funding source 
 You are requested to identify who provided financial support for the conduct of the research and/or 
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in 
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to 




 Please visit our Open Access page from the Journal Homepage for more information. 
Language (usage and editing services) 
 Please write your text in good English (American or British usage is accepted, but not a mixture of 
these). Authors who feel their English language manuscript may require editing to eliminate possible 
grammatical or spelling errors and to conform to correct scientific English may wish to use the English 
Language Editing service  available from Elsevier's Author Services. 
Informed consent and patient details 
 Studies on patients or volunteers require ethics committee approval and informed consent, which 
should be documented in the paper. Appropriate consents, permissions and releases must be obtained 
where an author wishes to include case details or other personal information or images of patients 
and any other individuals in an Elsevier publication. Written consents must be retained by the author 
but copies should not be provided to the journal. Only if specifically requested by the journal in 
exceptional circumstances (for example if a legal issue arises) the author must provide copies of the 
consents or evidence that such consents have been obtained. For more information, please review the 
Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals . Unless 
you have written permission from the patient (or, where applicable, the next of kin), the personal 
details of any patient included in any part of the article and in any supplementary materials (including 
all illustrations and videos) must be removed before submission. 
Submission 
 Our online submission system guides you stepwise through the process of entering your article 
details and uploading your files. The system converts your article files to a single PDF file used in 
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for 
final publication. All correspondence, including notification of the Editor's decision and requests for 
revision, is sent by e-mail. 
Please submit your article via https://www.editorialmanager.com/seizure/ 
Referees 
 Please submit the names and institutional e-mail addresses of several potential referees. For more 
details, visit our Support site . Note that the editor retains the sole right to decide whether or not the 
suggested reviewers are used. 
PREPARATION 
NEW SUBMISSIONS 
 Submission to this journal proceeds totally online and you will be guided stepwise through the creation 
and uploading of your files. The system automatically converts your files to a single PDF file, which 
is used in the peer-review process. 
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file 
to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout 
that can be used by referees to evaluate your manuscript. It should contain high enough quality 
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figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at 
the initial submission. Please note that individual figure files larger than 10 MB must be uploaded 
separately. 
References 
 There are no strict requirements on reference formatting at submission. References can be in any 
style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/ 
book title, chapter title/article title, year of publication, volume number/book chapter and the article 
number or pagination must be present. Use of DOI is highly encouraged. The reference style used by 
the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing 
data will be highlighted at proof stage for the author to correct. 
Formatting requirements 
 There are no strict formatting requirements but all manuscripts must contain the essential elements 
needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and 
Methods, Results, Conclusions, Artwork and Tables with Captions. 
If your article includes any Videos and/or other Supplementary material, this should be included in 
your initial submission for peer review purposes. 
Divide the article into clearly defined sections. 
Figures and tables embedded in text 
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 Please ensure the figures and the tables included in the single file are placed next to the relevant text 
in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should 
be placed directly below the figure or table. 
Peer review 
 This journal operates a single blind review process. All contributions will be initially assessed by the 
editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of 
two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible 
for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More 
information on types of peer review . 
REVISED SUBMISSIONS 
Use of word processing software 
 Regardless of the file format of the original submission, at revision you must provide us with an 
editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting 
codes will be removed and replaced on processing the article. The electronic text should be prepared 
in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with 
Elsevier ). See also the section on Electronic artwork. 
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' 
functions of your word processor. 
Article structure 
Subdivision - unnumbered sections 
 Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading 
should appear on its own separate line. Subsections should be used as much as possible when 
crossreferencing 
text: refer to the subsection by heading as opposed to simply 'the text'. 
Introduction 
 State the objectives of the work and provide an adequate background, avoiding a detailed literature 
survey or a summary of the results. 
Material and methods 
 Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods 
that are already published should be summarized, and indicated by a reference. If quoting directly 
from a previously published method, use quotation marks and also cite the source. Any modifications 
to existing methods should also be described. 
Theory/calculation 
 A Theory section should extend, not repeat, the background to the article already dealt with in the 
Introduction and lay the foundation for further work. In contrast, a Calculation section represents a 
practical development from a theoretical basis. 
Results 
 Results should be clear and concise. 
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Results should usually be presented in graphic or tabular form, rather than discursively. There should 
be no duplication in text, tables and figures. Experimental conclusions should normally be based 
on adequate numbers of observations with statistical analysis of variance and the significance of 
differences. The number of individual values represented by a mean should be indicated. 
Discussion 
 This should explore the significance of the results of the work, not repeat them. Avoid extensive 
citations and discussion of published literature. Speculative discussion is not discouraged, but the 
speculation should be based on the data presented and identified as such. 
In most cases a discussion of the limitations is appropriate and should be included in this section 
of the manuscript. 
Conclusions 
 The main conclusions of the study may be presented in a short Conclusions section, which may stand 
alone or form a subsection of a Discussion or Results and Discussion section. 
Appendices 
 If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in 
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, 
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc. 
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NEW - Reporting Guidelines and Checklists 
 To ensure a high and consistent quality of research reporting, Full Length Articles, Short 
Communications and Clinical Letters, must contain sufficient information to allow readers to 
understand how a study was designed and conducted. For review articles, systematic or narrative, 
readers should be informed of the rationale and details behind the literature search strategy. 
To achieve this goal, Seizure requires that authors upload a completed checklist for the appropriate 
reporting guideline during original submission. Taking the time to ensure your manuscript addresses 
basic reporting prerequisites will greatly improve your manuscript, and enhance the likelihood of 
publication. These checklists serve as a guide for the editors and reviewers as they evaluate your 
paper. 
The EQUATOR Network (https://www.equator-network.org/ ) is an excellent resource for key reporting 
guidelines, checklists, and flow diagrams. These guidelines should be especially useful for Seizures' 
authors. 
Click on the checklist that applies to your manuscript, download it to your computer, fill it out 
electronically, "save as," and upload it with your manuscript when you submit. Links to mandatory 
flow diagrams also are provided. Below are the most commonly used checklists but please note that 
the Equator Network provides many others (e.g. TRIPOD, SRQR, etc.) and it is up to the authors to 
select the one most appropriate for their study. 
Randomized Controlled Trials - CONSORT  - Consolidated Standards of Reporting Trials 
Observational Studies - STROBE  - Strengthening the Reporting of Observational studies in 
Epidemiology 
Systematic Review of Controlled Trials - PRISMA  - Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses 
Study of Diagnostic accuracy/assessment scale - STARD  - Standards for the Reporting of Diagnostic 
Accuracy Studies 
For psychometric studies the editors recommend either the COSMIN  or GRRAS  guideline, though the 
final choice is up to the author. 
During the submission process when you are prompted to state which checklist is used please type 
it into the provided text box for your manuscript or type Not Applicable if your paper is an Editorial, 
Letter to the Editor, Book Review etc. For the mandatory article types the system will ensure that you 
upload the file using the "Supporting File" file type, you should upload the appropriate checklist and 
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flow diagram. IT IS PERMISSIBLE TO ADD A COLUMN OR SPACE TO THE CHECKLIST THAT SPECIFIES 
WHERE IN THE MANUSCRIPT EACH COMPONENT HAS BEEN FOLLOWED AND USE THAT FOR YOUR 
UPLOAD. YOU MAY NEED TO DO THIS FOR STROBE AS WELL AS OTHERS. THE LATEST STROBE FORM 
IS AVAILABLE HERE 
Essential title page information 
 • Title.  Concise and informative. Titles are often used in information-retrieval systems. Avoid 
abbreviations and formulae where possible. 
• Author names and affiliations.  Please clearly indicate the given name(s) and family name(s) 
of each author and check that all names are accurately spelled. You can add your name between 
parentheses in your own script behind the English transliteration. Present the authors' affiliation 
addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase 
superscript letter immediately after the author's name and in front of the appropriate address. 
Provide the full postal address of each affiliation, including the country name and, if available, the 
e-mail address of each author. 
• Corresponding author.  Clearly indicate who will handle correspondence at all stages of refereeing 
and publication, also post-publication. This responsibility includes answering any future queries about 
Methodology and Materials. Ensure that the e-mail address is given and that contact details 
are kept up to date by the corresponding author. 
 • Present/permanent address.  If an author has moved since the work described in the article was 
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as 
a footnote to that author's name. The address at which the author actually did the work must be 
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes. 
Correct author name format 
 To prevent confusion please ensure that all author names are listed in the following format; first 
(Christian) name first and the last name (Surname/Family) last. This is specified because Spain, China 
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and some other countries often write them differently and this causes confusion with databases like 
MEDLINE. 
Highlights 
 Highlights are mandatory for this journal as they help increase the discoverability of your article via 
search engines. They consist of a short collection of bullet points that capture the novel results of 
your research as well as new methods that were used during the study (if any). Please have a look 
at the examples here: example Highlights . 
Highlights should be submitted in a separate editable file in the online submission system. Please 
use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including 
spaces, per bullet point). 
Abstract 
 A concise and factual abstract is required. The abstract should state briefly the purpose of the 
research, the principal results and major conclusions. An abstract is often presented separately from 
the article, so it must be able to stand alone. For this reason, References should be avoided, but if 
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should 
be avoided, but if essential they must be defined at their first mention in the abstract itself. 
Abstracts for regular articles and short communications should be structured, using the subheadings 
purpose, methods, results, conclusion. For reviews, the abstract does not need to follow this structure. 
They should be no longer than 250 words. Case reports (Clinical Letters) do not need to be preceded 
by an abstract. 
Graphical abstract 
 Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online 
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form 
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a 
separate file in the online submission system. Image size: Please provide an image with a minimum 
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office 
files. You can view Example Graphical Abstracts  on our information site. 
Authors can make use of Elsevier's Illustration Services  to ensure the best presentation of their images 
and in accordance with all technical requirements. 
Please note that the Highlights  section above only applies to Full Length Articles  and Reviews . 
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Keywords 
 Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding 
general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with 
abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will 
be used for indexing purposes. 
Abbreviations 
 Define abbreviations that are not standard in this field in a footnote to be placed on the first page 
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first 
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article. 
Acknowledgements 
 Collate acknowledgements in a separate section at the end of the article before the references and do 
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those 
individuals who provided help during the research (e.g., providing language help, writing assistance 
or proof reading the article, etc.). 
Formatting of funding sources 
 List funding sources in this standard way to facilitate compliance to funder's requirements: 
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; 
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes 
of Peace [grant number aaaa]. 
It is not necessary to include detailed descriptions on the program or type of grants and awards. When 
funding is from a block grant or other resources available to a university, college, or other research 
institution, submit the name of the institute or organization that provided the funding. 
If no funding has been provided for the research, please include the following sentence: 
This research did not receive any specific grant from funding agencies in the public, commercial, or 
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not-for-profit sectors. 
Nomenclature and units 
 Follow internationally accepted rules and conventions: use the international system of units (SI). 
If other quantities are mentioned, give their equivalent in SI. You are urged to consult IUPAC: 
Nomenclature of Organic Chemistry  for further information. 
Math formulae 
 Please submit math equations as editable text and not as images. Present simple formulae in 
line with normal text where possible and use the solidus (/) instead of a horizontal line for small 
fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often 
more conveniently denoted by exp. Number consecutively any equations that have to be displayed 
separately from the text (if referred to explicitly in the text). 
Footnotes 
 Footnotes should be used sparingly. Number them consecutively throughout the article. Many word 
processors build footnotes into the text, and this feature may be used. Should this not be the case, 
indicate the position of footnotes in the text and present the footnotes themselves separately at the 




 • Make sure you use uniform lettering and sizing of your original artwork. 
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier. 
• Number the illustrations according to their sequence in the text. 
• Use a logical naming convention for your artwork files. 
• Indicate per figure if it is a single, 1.5 or 2-column fitting image. 
• For Word submissions only, you may still provide figures and their captions, and tables within a 
single file at the revision stage. 
• Please note that individual figure files larger than 10 MB must be provided in separate source files. 
A detailed guide on electronic artwork  is available. 
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You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
 Regardless of the application used, when your electronic artwork is finalized, please 'save as' or 
convert the images to one of the following formats (note the resolution requirements for line drawings, 
halftones, and line/halftone combinations given below): 
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'. 
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi. 
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi. 
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi 
is required. 
Please do not: 
 • Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low. 
• Supply files that are too low in resolution. 
• Submit graphics that are disproportionately large for the content. 
Color artwork 
 Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or 
MS Office files) and with the correct resolution. If, together with your accepted article, you submit 
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear 
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations 
are reproduced in color in the printed version. For color reproduction in print, you will receive 
information regarding the costs from Elsevier after receipt of your accepted article . Please 
indicate your preference for color: in print or online only. Further information on the preparation of 
electronic artwork . 
Figure captions 
 Ensure that each illustration has a caption. A caption should comprise a brief title (not  on the figure 
itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but 
explain all symbols and abbreviations used. 
Text graphics 
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 Text graphics may be embedded in the text at the appropriate position. See further under Electronic 
artwork. 
Tables 
 Please submit tables as editable text and not as images. Tables can be placed either next to the 
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in 
accordance with their appearance in the text and place any table notes below the table body. Be 
sparing in the use of tables and ensure that the data presented in them do not duplicate results 
described elsewhere in the article. Please avoid using vertical rules and shading in table cells. 
References 
Citation in text 
 Please ensure that every reference cited in the text is also present in the reference list (and vice 
versa). Any references cited in the abstract must be given in full. Unpublished results and personal 
communications are not recommended in the reference list, but may be mentioned in the text. If these 
references are included in the reference list they should follow the standard reference style of the 
journal and should include a substitution of the publication date with either 'Unpublished results' or 
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted 
for publication. 
Web references 
 As a minimum, the full URL should be given and the date when the reference was last accessed. Any 
further information, if known (DOI, author names, dates, reference to a source publication, etc.), 
should also be given. Web references can be listed separately (e.g., after the reference list) under a 
different heading if desired, or can be included in the reference list. 
Data references 
 This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them 
in your text and including a data reference in your Reference List. Data references should include the 
following elements: author name(s), dataset title, data repository, version (where available), year, 
and global persistent identifier. Add [dataset] immediately before the reference so we can properly 
identify it as a data reference. The [dataset] identifier will not appear in your published article. 
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References in a special issue 
 Please ensure that the words 'this issue' are added to any references in the list (and any citations in 
the text) to other articles in the same Special Issue. 
Reference management software 
 Most Elsevier journals have their reference template available in many of the most popular reference 
management software products. These include all products that support Citation Style Language 
styles , such as Mendeley . Using citation plug-ins from these products, authors only need to select 
the appropriate journal template when preparing their article, after which citations and bibliographies 
will be automatically formatted in the journal's style. If no template is yet available for this journal, 
please follow the format of the sample references and citations as shown in this Guide. If you use 
reference management software, please ensure that you remove all field codes before submitting 
the electronic manuscript. More information on how to remove field codes from different reference 
management software . 
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following 
link: 
http://open.mendeley.com/use-citation-style/seizure-european-journal-of-epilepsy 
 When preparing your manuscript, you will then be able to select this style using the Mendeley plugins 
for Microsoft Word or LibreOffice. 
Reference formatting 
 There are no strict requirements on reference formatting at submission. References can be in any 
style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/ 
book title, chapter title/article title, year of publication, volume number/book chapter and the article 
number or pagination must be present. Use of DOI is highly encouraged. The reference style used by 
the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data 
will be highlighted at proof stage for the author to correct. If you do wish to format the references 
yourself they should be arranged according to the following examples: 
Reference style 
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Text:  Indicate references by number(s) in square brackets in line with the text. The actual authors 
can be referred to, but the reference number(s) must always be given. 
List:  Number the references (numbers in square brackets) in the list in the order in which they appear 
in the text. 
Examples: 
 Reference to a journal publication: 
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 
2010;163:51–9. https://doi.org/10.1016/j.Sc.2010.00372. 
Reference to a journal publication with an article number: 
[2] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. Heliyon. 
2018;19:e00205. https://doi.org/10.1016/j.heliyon.2018.e00205 
Reference to a book: 
[3] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000. 
Reference to a chapter in an edited book: 
[4] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith 
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304. 
Reference to a website: 
[5] Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/ 
aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 13 March 2003]. 
Reference to a dataset: 
[dataset] [6] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt 
disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/ 
xwj98nb39r.1. 
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 
should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for 
Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples 
of Formatted References ). 
Journal abbreviations source 
 Journal names should be abbreviated according to the List of Title Word Abbreviations . 
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Video 
 Elsevier accepts video material and animation sequences to support and enhance your scientific 
research. Authors who have video or animation files that they wish to submit with their article are 
strongly encouraged to include links to these within the body of the article. This can be done in the 
same way as a figure or table by referring to the video or animation content and noting in the body 
text where it should be placed. All submitted files should be properly labeled so that they directly 
relate to the video file's content. In order to ensure that your video or animation material is directly 
usable, please provide the file in one of our recommended file formats with a preferred maximum 
size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in 
the electronic version of your article in Elsevier Web products, including ScienceDirect . Please supply 
'stills' with your files: you can choose any frame from the video or animation or make a separate 
image. These will be used instead of standard icons and will personalize the link to your video data. For 
more detailed instructions please visit our video instruction pages . Note: since video and animation 
cannot be embedded in the print version of the journal, please provide text for both the electronic 
and the print version for the portions of the article that refer to this content. 
Data visualization 
 Include interactive data visualizations in your publication and let your readers interact and engage 
more closely with your research. Follow the instructions here  to find out about available data 
visualization options and how to include them with your article. 
Supplementary material 
 Supplementary material such as applications, images and sound clips, can be published with your 
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel 
or PowerPoint files will appear as such online). Please submit your material together with the article 
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to 
supplementary material during any stage of the process, please make sure to provide an updated file. 
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option 
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in Microsoft Office files as these will appear in the published version. 
Research data 
 This journal encourages and enables you to share data that supports your research publication 
where appropriate, and enables you to interlink the data with your published articles. Research data 
refers to the results of observations or experimentation that validate research findings. To facilitate 
reproducibility and data reuse, this journal also encourages you to share your software, code, models, 
algorithms, protocols, methods and other useful materials related to the project. 
Below are a number of ways in which you can associate data with your article or make a statement 
about the availability of your data when submitting your manuscript. If you are sharing data in one of 
these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to 
the "References" section for more information about data citation. For more information on depositing, 
sharing and using research data and other relevant research materials, visit the research data  page. 
Data linking 
 If you have made your research data available in a data repository, you can link your article directly to 
the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with 
relevant repositories, giving readers access to underlying data that gives them a better understanding 
of the research described. 
There are different ways to link your datasets to your article. When available, you can directly link 
your dataset to your article by providing the relevant information in the submission system. For more 
information, visit the database linking page . 
For supported data repositories  a repository banner will automatically appear next to your published 
article on ScienceDirect. 
In addition, you can link to relevant data or entities through identifiers within the text of your 
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; 
PDB: 1XFN). 
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Mendeley Data 
 This journal supports Mendeley Data, enabling you to deposit any research data (including raw and 
processed data, video, code, software, algorithms, protocols, and methods) associated with your 
manuscript in a free-to-use, open access repository. During the submission process, after uploading 
your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley 
Data . The datasets will be listed and directly accessible to readers next to your published article online. 
For more information, visit the Mendeley Data for journals page . 
Data statement 
 To foster transparency, we encourage you to state the availability of your data in your submission. 
This may be a requirement of your funding body or institution. If your data is unavailable to access 
or unsuitable to post, you will have the opportunity to indicate why during the submission process, 
for example by stating that the research data is confidential. The statement will appear with your 
published article on ScienceDirect. For more information, visit the Data Statement page . 
Interactive Case Insights 
 The journal encourages authors to complement their Clinical Letters  with test 
questions that reinforce the key learning points. These author created questions are 
submitted along with the article (new or revised) and will be made available in 
ScienceDirect along with your paper. More information and examples are available at 
https://www.elsevier.com/about/content-innovation/interactive-case-insights . Test questions are 
created online at http://elsevier-apps.sciverse.com/GadgetICRWeb/verification . Create the test 
questions, save them as a file to your desktop, and submit along with your (new or revised) manuscript 
through EES. That's it! For questions, please contact icihelp@elsevier.com. 
AFTER ACCEPTANCE 
Online proof correction 
 To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof 
corrections within two days. Corresponding authors will receive an e-mail with a link to our online 
proofing system, allowing annotation and correction of proofs online. The environment is similar to 
MS Word: in addition to editing text, you can also comment on figures/tables and answer questions 
from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing 
you to directly type your corrections, eliminating the potential introduction of errors. 
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If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions 
for proofing will be given in the e-mail we send to authors, including alternative methods to the online 
version and PDF. 
We will do everything possible to get your article published quickly and accurately. Please use this 
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and 
figures. Significant changes to the article as accepted for publication will only be considered at this 
stage with permission from the Editor. It is important to ensure that all corrections are sent back 
to us in one communication. Please check carefully before replying, as inclusion of any subsequent 
corrections cannot be guaranteed. Proofreading is solely your responsibility. 
Offprints 
 The corresponding author will, at no cost, receive 25 free paper offprints, or alternatively a customized 
Share Link  providing 50 days free access to the final published version of the article on ScienceDirect . 
The Share Link can be used for sharing the article via any communication channel, including email 
and social media. For an extra charge, paper offprints can be ordered via the offprint order form 
which is sent once the article is accepted for publication. Both corresponding and co-authors may 
order offprints at any time via Elsevier's Author Services . Corresponding authors who have published 
their article gold open access do not receive a Share Link as their final published version of the article 
is available open access on ScienceDirect and can be shared through the article DOI link. 
AUTHOR INQUIRIES 
 Visit the Elsevier Support Center  to find the answers you need. Here you will find everything from 
Frequently Asked Questions to ways to get in touch. 
You can also check the status of your submitted article  or find out when your accepted article will 
be published . 






































Appendix B: Reviewer comments 
 
Comments from the editors and reviewers: 
-Reviewer 1 
 
  -  
This is a concise review. 
I have some minor suggestions: 
When there is no firm conclusion from the literature with regard to the dose and duration of 
oral therapy with prednisolone, the authors should clarify that the content and the guideline in 
Figure 1 is their expert opinion. 
Figure 1. the title should be more informative of the content. 
Figure 1. the layout has a problem in the file, please recheck! 





  -  
This an an important novel review. The review was driven by the need to develop a 
recommendation to standardize a safe and effective regimen using oral steroids over other 
agents, such as ACTH and vigabatrin in low and middle income countries, where acess to 
internationally recommended agents are lacking.  Oral steroids are there used because of the 
lower price. Also in other parts of the world predniolone is increasingly used because of its 
efficacy and  easiness to administer (orally). 
The authors review carefully already a large existing  literature. Eighteen studies (14 
addressing the intervention and immediate outcome) were found between 1990-2017 (Table 
1). 
 However, it can be seen that  there are still many unmet questions concerning the use of 
(prednisone) and prednisolone: optimal dose, duration of the therapy, efficacy, relapse rate 
and long-term effects. Furthermore comparison with other 1-line drugs ACTH and vigabatrin 
are insufficiently studied. The studies are inhomogenous and difficult to compare. 
Randomized controlled studies are needed. 
Systematic review, P. 6: 4th line n=4:  ”long-term outcome” (give the follow-up time). Did 
the author mean Waningshire et al, Y et al , Lux et al, Ware et al  with long-term studies ??? 
At the end  of the Systematic review the authors present the Practice parameters of AAN. 
They should also give the Class ranking used in Table 1. 
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Management of epileptic spasms Page 7 (middle chapter). The authors give a very 
important statement which might distinguish prednisone from prednisolone. They are 
refering  Reference 24. This reference  mentions it,  but no original reference is included. 
Prednisone has no glucocorticoid effect. It has to be metabolized to prednisolone to have any 
effect. The same mechanism is happening: inactive cortisone has to be changed to cortisol 
(via 11beta-hydroxisteroiddehydrogenase type 1).  These conversions might indeed be 
defective at the age of less than 6 months. This is very crucial finding and might partly 
explain why prednisone is  ”ineffective” in treatment of infantile spasms reported in 
litterature. Add original reference if possible. (The diffrent dose might, of course, be 
also  important). 
Page 8: At bottom of last prgh; Add the bolded to the text.  Of the identified studies assessing 
the use of prednisone, or methylprednisone there was marked variation evident in study 
methologies (inclusion criteria, drop-outs,treatment lag, definion of response, 
proportion of low-risk/high-risk, cryptogenic/symptomatic patients, dose and duration 
of therapy and length of follow-up), limiting the comparison across the studies. 
 Some studies have selection bias of low-risk patients where the effect of therapy is high 
(Baram  et al 1996,Lux et al 2004, O`Callaghan et al 2017); some others give the therapy to 
all consequent patients (Knupp et al 2016 ) and the therapeutic response seems to be less. The 
studies with large numbers of low-risk patients could be marked by asterix and foot-note in 
Table 1. 
 Page 9, 2nd prgh: last sentence ”For optimal short-term care, combination therapy may be 
needed as evidenced by ICISS study (29). ---- Relapses andl long-term cognitive outcome is 
not known in ICISS study. The patients have adverse effects of both drugs (personal opinion, 
not to be added to the review ( Riikonen The Lancet Neurology 2015). 
P 10: Adverse effects. 2nd sentence ”other side effects include increased appetite, weight 
gain, hypertension, hypertrophic cardiomyopathy, cushingoid faces, irritabilty, glucosuria, 
cerebral atrophy, hypopituitary-adrenal axis insufficiency and immunosuppression.  
The followind sentence should be deleted starting ”Kossoff… ….”  
In the Kossoff et al study irritability, edema, hypertension and excessive weight gain were 
seen in 12/15 patients in ACTH treatment and 8/15 in prednisolone. The a.m. adverse effects 
are difficult to measure, and the difference was not significant. 
P 11 ”cryptogenic” cause (patients with normal development before onset of infantile spasms 
and no known etiology, MRI normal). 
In Conclusion 
I agree with the following conclusion 
Page 12: ”In summary, there is level C evidence to support the efficacy of oral corticosteroids 
for the acute control of epileptic spasms and EEG resolution, Use of oral corticosteroids in 
comparison to interenationally recommended intervention of ACTH is lecvel U.” 
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Figure 1 is excellent.  
Table 1 
 Demarest Short-term Vigabatrin or 5.2 prednisolone or 8, ACTH 10,2 What are these 
numbers? 
Knupp 7th column: last word : ..and ..?? 
Mohammed et al 2011 (GOSH, UK) ….  What is GOSH ??? 
References are largely lacking. In Table 1 there are many authors without references. The 
references should be added to Reference list. 
  
Demarest et al  2017, Tang-Wai et al. 2017, Bara et al ?? (Baram?), Ware et al,. 2012, 
Appleton et al .Elterman, Aicardi, Noureen et al 2012, Azam et al 2005 . Authors of 
Reference 15 should be Gronseth G, French F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
